<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576496</url>
  </required_header>
  <id_info>
    <org_study_id>EDO-S101-1001</org_study_id>
    <nct_id>NCT02576496</nct_id>
  </id_info>
  <brief_title>Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma-EDO GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma-EDO GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101)&#xD;
      in patients with relapsed/refractory hematologic malignancies. All patients will receive&#xD;
      tinostamustine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tinostamustine is a new chemical entity, a first-in-class fusion molecule of an alkylator,&#xD;
      bendamustine and a histone-deacetylase inhibitor (HDACi), vorinostat. It is anticipated that&#xD;
      tinostamustine may have activity in various hematological malignancies and solid tumors.&#xD;
&#xD;
      The study consists of 2 stages:&#xD;
&#xD;
        -  Stage 1: Dose Escalation to determine Maximum Tolerated Dose (MTD) at the optimal&#xD;
           infusion time and the pharmacokinetic (PK) profiles; is expected to enroll between 21&#xD;
           and 48 patients. Stage 1 has now been completed.&#xD;
&#xD;
        -  Stage 2: Expansion in five Cohorts, in which approximately 12-16 patients will be&#xD;
           enrolled per cohort, for a maximum of 70 patients.&#xD;
&#xD;
      In Stage 1, tinostamustine doses were escalated following the standard 3+3 design. The&#xD;
      decision to escalate to the next dose level occurred after all cohort patients completed 3&#xD;
      weeks (21 days) of observation and have been evaluated for safety and toxicity.The starting&#xD;
      dose was a 1 hour infusion of 20 mg/m2, and the maximum dose level was 150 mg/m2. Reduced&#xD;
      infusion times of 45 minutes and 30 minutes were assessed once the maximum tolerated dose at&#xD;
      a 1-hour infusion was determined.&#xD;
&#xD;
      In Stage 2, five cohorts of patients (with relapsed/refractory multiple myeloma (MM);&#xD;
      relapsed/refractory Hodgkin's lymphoma; relapsed/refractory peripheral T-cell lymphoma&#xD;
      (PTCL); relapsed/refractory cutaneous T-cell lymphoma (CTCL); and relapsed/refractory T-cell&#xD;
      Prolymphocytic leukemia (T-PLL) will be enrolled and treated at the recommended Phase 2 dose&#xD;
      (RP2D) based on results of Stage 1. For MM patients, treatment will occur on Day 1 and Day 15&#xD;
      of a 28 day cycle. For lymphoma patients, treatment will occur on Day 1 of a 21 day cycle.&#xD;
      Patients in each stage of the study are expected to receive a median of four Cycles of&#xD;
      therapy, and the maximum number of treatment Cycles allowed is 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>10-20 months from beginning of stage 2</time_frame>
    <description>Determine overall response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical benefit rate by cohort</measure>
    <time_frame>10-20 months from beginning of stage 2</time_frame>
    <description>Determine clinical benefit rate by cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of selected doses in expanded population</measure>
    <time_frame>36 months from beginning stage 2</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE V4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to objective response</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Evaluate time to objective response by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Evaluate duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>32-36 months after beginning stage 2</time_frame>
    <description>Determine time to progression free survival time for patients who received the RP2D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>32-36 months after beginning stage 2</time_frame>
    <description>Determine the overall survival time for patients who received the RP2D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Determine Cmax using the PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax)</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Determine Tmax using the PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken for the plasma concentration to fall by half its original value (t1/2)</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Determine t1/2 using the PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Determine area under the plasma drug concentration-time curve using the PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT (QTc) analysis</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>To perform a concentration corrected QT analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events (TEAEs). TEAEs will be assessed by NCI-CTCAE 4.03</measure>
    <time_frame>10-20 months after beginning stage 2</time_frame>
    <description>Patient safety data will be summarized by disease cohort as well as overall disease cohorts pooled (i.e., MM, Hodgkin's lymphoma, non-Hodgkin's lymphoma, PTCL, T- PLL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Cutaneous T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tinostamustine (EDO-S101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinostamustine</intervention_name>
    <arm_group_label>Tinostamustine (EDO-S101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient willing and able to sign an informed consent.&#xD;
&#xD;
          2. Patients age ≥18 years at signing the informed consent.&#xD;
&#xD;
          3. Life expectancy &gt; 3 months.&#xD;
&#xD;
          4. Diagnosis of relapsed or refractory lymphoid malignancy for which there are no&#xD;
             available therapies.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          6. Absolute Neutrophil Count &gt;1,000 µL&#xD;
&#xD;
          7. Platelets ≥100,000 µL&#xD;
&#xD;
          8. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          9. Total bilirubin &lt;2.0 mg/dL unless elevated due to known Gilbert's syndrome.&#xD;
&#xD;
         10. Creatinine ≤1.5 x ULN.&#xD;
&#xD;
         11. Serum potassium and magnesium at least at the lowest limit of normal (LLN) at&#xD;
             baseline(before every IMP administration; if it is below LNN, (supplementation is&#xD;
             permissible).&#xD;
&#xD;
         12. Males and females of child-bearing potential, and their partners, must be willing to&#xD;
             use at least two effective forms of birth control during the study drug administration&#xD;
             and for at least 90 days after the administration of the study drug to be eligible to&#xD;
             participate. Vasectomized partners and patients must be willing to use a secondary&#xD;
             method of effective birth control. Sexual abstinence is considered a highly effective&#xD;
             method only if defined as refraining from heterosexual intercourse during the entire&#xD;
             period of risk associated with the study treatment. The reliability of sexual&#xD;
             abstinence needs to be evaluated in relation to the duration of the clinical trial and&#xD;
             the preferred and usual lifestyle of the patient.&#xD;
&#xD;
        Specific Eligibility Criteria for Each Patient Cohort in Stage 2 Phase of the Study&#xD;
&#xD;
        Cohort 1: relapsed/refractory multiple myeloma 1. At least one line and a maximum of five&#xD;
        prior standard systemic therapies and no other standard therapy available with proven&#xD;
        clinical benefit.&#xD;
&#xD;
        Cohort 2: relapsed/refractory Hodgkin's lymphoma&#xD;
&#xD;
        1. At least three lines of prior therapy and no other standard therapy available with&#xD;
        proven clinical benefit.&#xD;
&#xD;
        Cohort 4: relapsed/refractory cutaneous T-cell lymphoma (CTCL), subtypes mycosis fungoides&#xD;
        (MF) and Sézary syndrome (SS)&#xD;
&#xD;
          1. Only CTCL patients with histologically or cytologically confirmed MF or SS with stage&#xD;
             IIb to IVb disease based on modified ISCL/EORTC staging.&#xD;
&#xD;
          2. At least one line and a maximum of four prior standard systemic therapies and no other&#xD;
             standard therapy available with proven clinical benefit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any central nervous system involvement.&#xD;
&#xD;
          2. Patient who had a hematologic malignancy that has transformed.&#xD;
&#xD;
          3. Any patient who has relapsed within 100 days of stem cell infusion following an&#xD;
             allogenic or an autologous bone marrow transplant.&#xD;
&#xD;
          4. Patients with corrected QT (QTc) interval (Fridericia's formula) &gt; 450 msec.&#xD;
&#xD;
          5. Patients who are on treatment with drugs known to prolong the QT/QTc interval.&#xD;
&#xD;
          6. Any serious medical condition that interferes with adherence to study procedures.&#xD;
&#xD;
          7. Patients with a history of another malignancy diagnosed within three years of study&#xD;
             enrollment excluding basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
&#xD;
          8. Pregnant or breast feeding females.&#xD;
&#xD;
          9. New York Heart Association (NYHA) stage III/IV congestive heart failure. The following&#xD;
             arrhythmias not adequately controlled, active: atrial fibrillation/flutter with poor&#xD;
             rate control, documented sustained ventricular tachycardia (defined as &gt;30 seconds or&#xD;
             requiring cardioversion before 30 seconds have elapsed) or TdP.&#xD;
&#xD;
         10. Active infections, or other significant co-morbidities [(e.g., active central nervous&#xD;
             system metastases and/or carcinomatous meningitis, active infection requiring systemic&#xD;
             therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis&#xD;
             B or Hepatitis C.&#xD;
&#xD;
         11. Previous cancer therapies within three (3) weeks of dosing as long as the patient has&#xD;
             recovered to eligibility levels prior to treatment in this study.&#xD;
&#xD;
         12. Use of other investigational agents within 30 days or 5 half-lives prior to the first&#xD;
             dose of study drug unless patient has recovered from any related toxicities ≥ Grade 1.&#xD;
&#xD;
         13. Steroid treatment within seven (7) days prior to study treatment. Patients that&#xD;
             require intermittent use of bronchodilators, topical steroids or local steroid&#xD;
             injections will not be excluded from the study. Patients who have been stabilized to&#xD;
             10 mg PO QD or less seven (7) days prior to study drug administration are allowed.&#xD;
&#xD;
         14. Patients on Valproic Acid for any indication (epilepsy, mood disorder) must be&#xD;
             excluded from the trial .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pier L Zinzani, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna Medical Center, Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MDACC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>CS 3001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gandhi L Damaj, MD</last_name>
      <phone>00 33 231 06 25 36</phone>
      <email>damag-gl@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Marin</last_name>
      <phone>00 33 231 27 20 72</phone>
      <email>marin.e@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gandhi L Damaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Tournilhac</last_name>
      <email>otournilhac@chu-clerrrand.frmontfe</email>
    </contact>
    <contact_backup>
      <last_name>Christelle Latière</last_name>
      <phone>334 73 750 674</phone>
      <email>clatiere@chu-clermontferrand.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Tournilhac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Morschhauser</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Nung</last_name>
      <phone>33 20 44 40 22</phone>
      <email>alexandre.nung@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Franck Morschhauser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Aude Blanloeil</last_name>
      <email>marieaude.blanloeil@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Moreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal Bouabdallah</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Franzl</last_name>
      <phone>335 57 62 33 23</phone>
      <email>nathalie.franzl@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Kamal Bouabdallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Ghesquieres, MD</last_name>
      <phone>00 33 478 86 43 07</phone>
      <email>herve.ghesquieres@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie Tronchon</last_name>
      <phone>00 33 478 84 43 35</phone>
      <email>virginie.tronchon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Herve Ghesquieres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm, Department of Internal Medicine III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayten Sagir</last_name>
      <phone>0049-731-500-45927</phone>
      <email>Ayden.Sagir@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Viardot, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &quot;L. A. Seràgnoli&quot;, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <phone>+39 0512143680</phone>
      <email>pierluigi.zinzani@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Fondazione 'G. Pascale'</name>
      <address>
        <city>Naples</city>
        <zip>I-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pinto, MD</last_name>
      <phone>+39 081 5903 382</phone>
      <email>apinto.int.napoli@tin.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josée Zijlstra, MD</last_name>
      <phone>+31 20 4442604</phone>
      <email>J.Zijlstra@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Maaike Leidekker</last_name>
      <phone>+31 20 4442639</phone>
      <email>m.leidekker@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Josée Zijlstra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieternella Lugtenburg, MD</last_name>
      <phone>+31 10 7033123</phone>
      <email>p.lugtenburg@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Pieternella Lugtenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia de Barcelona</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana S Balari, MD</last_name>
      <phone>+34 93 260 72 10</phone>
      <email>asureda@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Ana S Balari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria V Mateos, MD</last_name>
      <phone>+34 678438203</phone>
      <email>mvmateos@usal.es</email>
    </contact>
    <investigator>
      <last_name>Maria V Mateos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Ocio, MD</last_name>
      <phone>+34 649-391848</phone>
      <email>ocioem@unican.es</email>
    </contact>
    <investigator>
      <last_name>Enrique Ocio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Driessen, MD</last_name>
      <phone>41 71 494 11 62</phone>
      <email>christoph.driessen@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Driessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1 clinical trial</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>cutaneous T-cell lymphoma</keyword>
  <keyword>tinostamustine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>relevant patient listing data of de-identified patients may be reviewed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

